MAPT and Alzheimer disease: For example, a recent study by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has suggested that to test for structural changes on MRI in a population of individuals with preclinical AD enriched on the basis of Aβ and tau biomarker positivity, sample size estimates are prohibitively large [3].